Literature DB >> 16760006

Mouse models in oncogenesis and cancer therapy.

M V Céspedes1, I Casanova, M Parreño, R Mangues.   

Abstract

Animal models have been critical in the study of the molecular mechanisms of cancer and in the development of new antitumor agents; nevertheless, there is still much room for improvement. The relevance of each particular model depends on how close it replicates the histology, physiological effects, biochemical pathways and metastatic pattern observed in the same human tumor type. Metastases are especially important because they are the main determinants of the clinical course of the disease and patient survival, and are the target of systemic therapy. The generation of clinically relevant models using the mouse requires their humanization, since differences exist in transformation and oncogenesis between human and mouse. Although genetically modified (GM) mice have been instrumental in understanding the molecular mechanisms involved in tumor initiation, they have been less successful in replicating advanced cancer. Moreover, a particular genetic alteration frequently leads to different tumor types in human and mouse and to lower metastastatic rates in GM mice than in humans. These findings question the capacity of current GM mouse carcinoma models to predict clinical response to therapy. On the other hand, orthotopic (ORT) xenografts of human tumors, or tumor cell lines, in nude mice reproduce the histology and metastatic pattern of most human tumors at advanced stage. Using ex vivo genetic manipulation of human tumor cells, ORT models can be used to molecularly dissect the metastatic process and to evaluate in vivo tumor response to therapy, using non-invasive procedures. Nevertheless, this approach is not useful in the study of the initial stages of tumorigenesis or the contribution of the immune system in this process. Despite ORT models are more promising than the most commonly used subcutaneous xenografts in preclinical drug development, their capacity to predict clinical response to antitumor agents remains to be studied. Humanizing mouse models of cancer will most likely require the combined use of currently available methodologies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760006     DOI: 10.1007/s12094-006-0177-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  70 in total

Review 1.  Manipulating the germline: its impact on the study of carcinogenesis.

Authors:  A R Clarke
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

Review 2.  Validity of mouse mammary tumour models for human breast cancer: comparative pathology.

Authors:  R D Cardiff
Journal:  Microsc Res Tech       Date:  2001-01-15       Impact factor: 2.769

Review 3.  Fibronectin and its integrin receptors in cancer.

Authors:  E Ruoslahti
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

Review 4.  Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models?

Authors:  R M Hoffman
Journal:  J Cell Biochem       Date:  1994-09       Impact factor: 4.429

Review 5.  Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

Authors:  J M Venditti; R A Wesley; J Plowman
Journal:  Adv Pharmacol Chemother       Date:  1984

6.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

Review 7.  Preclinical models for the evaluation of targeted therapies of metastatic disease.

Authors:  S A Eccles; G Box; W Court; J Sandle; C J Dean
Journal:  Cell Biophys       Date:  1994

Review 8.  Animal models of breast cancer: their diversity and role in biomedical research.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors.

Authors:  Hashmat Sikder; David L Huso; Hong Zhang; Binghe Wang; Byungwoo Ryu; Sam T Hwang; Jonathan D Powell; Rhoda M Alani
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

10.  Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft.

Authors:  G Pratesi; C Manzotti; M Tortoreto; R A Audisio; F Zunino
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more
  45 in total

1.  Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.

Authors:  Chun Jiang; Xiao-Ping Yi; Hong Shen; Yi-Xiong Li
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  The use of chemokine-releasing tissue engineering scaffolds in a model of inflammatory response-mediated melanoma cancer metastasis.

Authors:  Cheng-Yu Ko; Lanxiao Wu; Ashwin M Nair; Yi-Ting Tsai; Victor K Lin; Liping Tang
Journal:  Biomaterials       Date:  2011-10-22       Impact factor: 12.479

Review 3.  Lung cancer cell lines as tools for biomedical discovery and research.

Authors:  Adi F Gazdar; Luc Girard; William W Lockwood; Wan L Lam; John D Minna
Journal:  J Natl Cancer Inst       Date:  2010-08-02       Impact factor: 13.506

4.  MicroRNA-886-3P functions as a tumor suppressor in small cell lung cancer.

Authors:  Jie Shen; Wei Zhou; Nan Bi; Yong-Mei Song; Fu-Quan Zhang; Qi-Min Zhan; Lv-Hua Wang
Journal:  Cancer Biol Ther       Date:  2018-09-19       Impact factor: 4.742

5.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

6.  Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.

Authors:  Rana P Singh; Komal Raina; Gagan Deep; Daniel Chan; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine.

Authors:  Yoko S DeRose; Keith M Gligorich; Guoying Wang; Ann Georgelas; Paulette Bowman; Samir J Courdy; Alana L Welm; Bryan E Welm
Journal:  Curr Protoc Pharmacol       Date:  2013-03

8.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

Review 9.  Rebuilding cancer metastasis in the mouse.

Authors:  Meera Saxena; Gerhard Christofori
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

Review 10.  Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research.

Authors:  Gunver S Kienle; Anja Glockmann; Michael Schink; Helmut Kiene
Journal:  J Exp Clin Cancer Res       Date:  2009-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.